Analyst: Genmab's progress with the FDA sends a positive signal
It's not surprising that the US FDA has accepted Genmab's application for the drug tisotumab vedotin, but it's a feather in the company's cap that the application received priority review status.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Genmab will probably manage better than the general stock market on Monday following the firm's Friday announcement that the US Food and Drug Administration (FDA) has accepted treating its – and Seagen's – biologics license application for the drug tisotumab vedotin in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA grants new Genmab drug priority review status
For subscribers
Genmab drug becomes more accessible in the US
For subscribers
